ATF6 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the 769-P human renal cell carcinoma line. This product comprises a heterogeneous pool of 769-P cells carrying diverse ATF6 gene disruptions introduced by CRISPR/Cas9, preserving genetic diversity and avoiding clonal selection artifacts. The polyclonal format is suited for population-level analyses of ATF6 function in unfolded protein response (UPR) and ER stress signaling.
The parental 769-P line originates from a clear cell renal cell carcinoma of proximal tubule epithelial origin. As a well-characterized adherent cancerous cell model, 769-P is extensively used in renal cancer research to study tumor biology, drug sensitivity, and stress responses. Its malignant context provides a relevant background for examining how ATF6-mediated UPR supports renal carcinoma cell adaptation and survival.
ATF6 encodes a transmembrane transcription factor central to the UPR. In unstressed cells, ATF6 is retained in the endoplasmic reticulum (ER) through interaction with BiP/GRP78. ER stress triggers BiP dissociation, allowing ATF6 trafficking to the Golgi, where sequential cleavage by S1P and S2P releases its cytoplasmic N-terminal domain. This active fragment enters the nucleus and, in complex with NF-Y/CBF, drives transcription of key genes: ER chaperones (GRP78/HSPA5, GRP94/HSP90B1, CALR), protein disulfide isomerases (PDIA4), and ER-associated degradation components (HERPUD1), along with the transcription factor XBP1. ATF6 thus augments ER protein-folding capacity and misfolded protein clearance, functioning in parallel with the IRE1 and PERK UPR branches.
In 769-P renal carcinoma cells, ATF6-dependent UPR signaling contributes to adaptive mechanisms that promote tumor cell survival and chemoresistance. Knockout of ATF6 in this polyclonal population permits dissection of its specific role in ER stress management and analysis of downstream targets such as GRP78 and HERPUD1 under stressors like tunicamycin or thapsigargin. This model is valuable for studying the link between oncogenic stress and proteostatic control in kidney cancer.
Key research applications include western blotting for ATF6 full-length and cleaved forms, RT-qPCR of UPR target transcripts, ATF6 luciferase reporter assays, and immunofluorescence to monitor ATF6 subcellular redistribution. Co-immunoprecipitation with BiP and viability assays under chemically induced ER stress further enable functional studies. The polyclonal pool is also compatible with pooled CRISPR screens and omics approaches. For additional technical information, please contact Ascent Research.
